Veeva Systems (VEEV) – Investment Analysts’ Recent Ratings Changes

A number of research firms have changed their ratings and price targets for Veeva Systems (NYSE: VEEV):

• 3/22/2026 – Veeva Systems was downgraded by Wall Street Zen from “buy” to “hold”.
• 3/14/2026 – Veeva Systems was upgraded by Wall Street Zen from “hold” to “buy”.
• 3/10/2026 – Veeva Systems had its “outperform” rating reaffirmed by William Blair.
• 3/9/2026 – Veeva Systems had its price target lowered by Citigroup Inc. from $319.00 to $291.00. They now have a “buy” rating on the stock.
• 3/5/2026 – Veeva Systems had its price target lowered by Canaccord Genuity Group Inc. from $280.00 to $235.00. They now have a “hold” rating on the stock.
• 3/5/2026 – Veeva Systems had its price target lowered by TD Cowen from $380.00 to $300.00. They now have a “buy” rating on the stock.
• 3/5/2026 – Veeva Systems had its price target raised by Stifel Nicolaus from $212.00 to $245.00. They now have a “buy” rating on the stock.
• 3/5/2026 – Veeva Systems had its price target lowered by Wells Fargo & Company from $333.00 to $317.00. They now have an “overweight” rating on the stock.
• 3/5/2026 – Veeva Systems had its “buy” rating reaffirmed by Truist Financial Corporation. They now have a $262.00 price target on the stock, down from $275.00.
• 3/5/2026 – Veeva Systems had its price target raised by UBS Group AG from $200.00 to $220.00. They now have a “neutral” rating on the stock.
• 3/5/2026 – Veeva Systems had its price target lowered by Royal Bank Of Canada from $330.00 to $275.00. They now have an “outperform” rating on the stock.
• 3/5/2026 – Veeva Systems had its price target lowered by Piper Sandler from $355.00 to $285.00. They now have an “overweight” rating on the stock.
• 3/5/2026 – Veeva Systems had its price target lowered by Needham & Company LLC from $355.00 to $270.00. They now have a “buy” rating on the stock.
• 3/5/2026 – Veeva Systems had its price target raised by Morgan Stanley from $205.00 to $215.00. They now have an “equal weight” rating on the stock.
• 2/26/2026 – Veeva Systems had its price target lowered by Stifel Nicolaus from $320.00 to $212.00. They now have a “buy” rating on the stock.
• 2/25/2026 – Veeva Systems had its price target lowered by Barclays PLC from $305.00 to $250.00. They now have an “overweight” rating on the stock.
• 2/24/2026 – Veeva Systems had its price target lowered by Oppenheimer Holdings, Inc. from $325.00 to $275.00. They now have an “outperform” rating on the stock.
• 2/20/2026 – Veeva Systems had its price target lowered by JPMorgan Chase & Co. from $330.00 to $296.00. They now have an “overweight” rating on the stock.
• 2/20/2026 – Veeva Systems had its price target lowered by UBS Group AG from $280.00 to $200.00. They now have a “neutral” rating on the stock.
• 2/17/2026 – Veeva Systems was upgraded by Morgan Stanley from “underweight” to “equal weight”. They now have a $205.00 price target on the stock, down from $222.00.

Insider Transactions at Veeva Systems

In other news, insider Thomas D. Schwenger sold 1,000 shares of the business’s stock in a transaction on Tuesday, January 13th. The stock was sold at an average price of $231.43, for a total value of $231,430.00. Following the sale, the insider owned 23,204 shares of the company’s stock, valued at approximately $5,370,101.72. The trade was a 4.13% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 10.30% of the stock is owned by corporate insiders.

Veeva Systems (NYSE: VEEV) is a cloud software company that develops industry-specific applications and data solutions for the global life sciences sector. Founded in 2007 and headquartered in Pleasanton, California, Veeva focuses on helping pharmaceutical, biotechnology, medical device and consumer health companies manage regulated content, clinical and regulatory processes, quality systems, and commercial operations in a compliant, cloud-native environment. The company completed its initial public offering in 2013 and has since expanded its product suite and international footprint.

Veeva’s product portfolio centers on its Vault platform and related application suites, which provide content and data management, clinical trial and regulatory workflows, quality management, and structured commercial capabilities such as customer relationship management and promotional content management.